A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder
Chen, Joseph C C, Sumner, Rachael L, Krishnamurthy Naga, Venkat, Hoeh, Nicholas, Ayeni, Hafis Adetokunbo, Singh, Vikrant, Sundram, Frederick, Campbell, Douglas, Muthukumaraswamy, Suresh
Published in Current controlled trials in cardiovascular medicine (10.02.2020)
Published in Current controlled trials in cardiovascular medicine (10.02.2020)
Get full text
Journal Article